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Abstract: Supramolecular hydrogels based on N-protected phenylalanine 
(Fmoc–Phe–OH) were used to encapsulate non-ionic surfactant vesicles 
(niosomes). The niosomes consisted of an amphiphilic lipid mixed with 
polysorbate-80 and electrostatically complexed with a fluorescently labelled 
oligodeoxynucleotide (FITC–ODN) as a model nucleic acid derivative. The 
diffusion properties of the supramolecular hydrogel were conveniently tuned by 
adding a small amount of k-carrageenan (#1% w/v) as a crosslinking agent. 
Interestingly, neither cationic niosomes nor the biopolymer additive significantly 
affected the hydrogelation properties of the amino acid-based low molecular 
weight (LMW) gelator. In vitro drug release experiments from Fmoc–Phe–OH 
hydrogels containing cationic niosomes were successfully carried out in the 
absence and in the presence of k-carrageenan. The niosomal ODN liberation in 
solution was fitted using Higuchi, Korsmeyer–Peppas and Weibull drug release 
models, showing the prevalence of diffusion mechanisms in each case. 
Moreover, the time release was easily prolonged by increasing the 
concentration of k-carrageenan. Preliminary transfection studies indicate the 
suitability of these supramolecular hybrid hydrogels to embed niosomal 
formulations and, consequently, for being used as tunable delivery vehicles for 
nucleic acids. 
 
 
 
 
INTRODUCTION. 
 
Since Wichterle and Lim reported for the first time the synthesis of 
crosslinked poly(hydroxyethylmethacrylate) (pHEMA) for biological use,1 
synthetic and natural polymer-based hydrogels have gained substantial 
importance over the years in a good number of biomedical, pharmaceutical and 
biotechnological applications such as tissue engineering, drug delivery systems 
or cell culture scaffolds.2–5 The research in this area has contributed to the 
development of novel smart polymer gel networks having specific responses to 
external stimuli such as pH, light, temperature or chemical additives,6–8 which 
could facilitate the controlled liberation of embedded therapeutic drugs.9 
In contrast to polymer or chemical gels10 that are based on covalent 
bonds, physical or supramolecular gels11 are typically made of low molecular 
weight (LMW) compounds self-assembled through non-covalent interactions 
(e.g., hydrogen-bonding, pi–pi stacking, van der Waals, dipole–dipole, charge-
transfer and coordination interactions). In general, such non-covalent nature of 
supramolecular gels provides reversible gel-to-sol phase transitions as 
response to external stimuli. The solid-like appearance and rheological 
properties of the gels result from the immobilization of the liquid (major 
component) into the interstices of a solid matrix (minor component) mainly 
through capillary forces.12 The formation of the 3D-network with numerous 
junction zones results from the entanglement of 1D-suprapolymeric strands of 
gelator molecules usually of nm diameters and mm lengths.13 The synthetic 
versatility of many LMW gelators together with their biocompatible properties 
have allowed their use in a number of biomedical applications including cell 
adhesion, cell growth, tissue engineering and controlled drug delivery.14–17 
Among the plethora of LMW compounds that are able to form supramolecular 
hydrogel networks, amino acid derivatives and peptide conjugates18–23 
constitute one of the most studied groups. Within this context, the use of 
phenylalanine (Phe) derivatives as hydrogelator was reported for the first time in 
2006.24,25 In 2011, Roy and Banerjee26 reported the ability of N-terminally Fmoc 
protected Phe, Fmoc–Phe–OH, to form stable and transparent hydrogels at 
concentrations as low as 0.1% w/v. 
On the other hand, the development of more efficient and safe strategies 
for the administration of a drug is a key step for the success in modern 
therapeutic processes. Besides the classical therapeutic approaches to find a 
drug, gene therapy and gene silencing strategies have emerged as promising 
treatment options for a number of diseases. However, the search of an optimal 
administration is a key to getting an efficient therapeutic action. Thus, colloidal 
drug delivery systems including nanoparticles, liposomes and hydrogels, among 
others, have experienced significant growth in recent years based on the 
necessity of optimizing the transportation of poorly-water soluble drugs as well 
as improving the bioavailability and pharmacokinetics of numerous nucleic acid 
therapeutics.27 Within this context, niosomes (non-ionic surfactant vesicles) 
have become promising candidates for drug delivery applications28,29 and an 
alternative to the use of liposomes, which are considered the keystone of 
particle-based carrier systems. This growing interest of niosomes is mainly due 
to their good physical stabilities, cost-effectiveness, easy large-scale synthesis 
and their structural similarities to liposomes. Moreover, they are able to 
efficiently entrap hydrophilic and lipophilic drugs either in aqueous 
compartments or in bilayer domains, respectively. This efficiency has been 
recently reported by some of us with the use of nioplexes, elaborated with 
cationic niosomes, for both in vitro and in vivo transfection experiments.30,31 
Although liposomes, niosomes and other conventional lipid particles have 
mainly prepared to obtain more efficient non-druggable therapeutic 
formulations, the stability of such particles may be lessened by the action of 
macrophages and their rapid renal clearance. Several approaches have been 
reported to overcome this drawback, including variation of particle size, surface 
charge, lipid composition or the addition of different ligands and/or 
receptors.32,33 Alternatively, the encapsulation of such colloidal particles either 
in synthetic34 or natural polymers-based hydrogels35 has also generated 
promising and fascinating hybrid materials that has helped to improve the 
efficacy of such liposomal formulations.36,37 In fact, this kind of entrapment has 
generated efficient colloidal particle protections and thereby has reduced both 
undesirable burst release effects and improved drug delivery when therapeutic 
molecules have been administered.38,39 More recently, novel hybrid materials 
like injectable hydrogels containing liposomes with self-healing or shear-
thinning properties have also proven to be another promising approach 
employed for therapeutic purposes.40 In particular, hydrogel synthesis from 
polymer–nanoparticle interactions41 or responsive hydrogel materials for 
intratumoral delivery have been designed for suitable in vitro and in vivo drug 
delivery processes and for some cancer treatments42 by increasing the efficacy 
and reducing toxicity, respectively. Recently, multidomain peptides (MDPs), 
which have the ability to self-assemble and generate nanofiber hydrogels, have 
also been used to entrap liposomes containing several growth factors.43,44 
In this work we describe the synthesis of lipid-based nioplexes bearing 
an oligodeoxynucleotide as a model biomolecule. These nioplexes were 
subsequently encapsulated within supramolecular hydrogels based on self-
assembled Fmoc–Phe–OH molecules.23 Some hydrogels were also physically 
crosslinked by the addition of k-carrageenan. In vitro release kinetics of the 
niosomal formulation from these hydrogels was investigated and adjusted to 
several mathematical models. Finally, the suitability of hybrid materials in the 
transfection of nucleic acids (e.g. antisense oligonucleotide and plasmid DNA) 
in cell culture was also evaluated. The overall concept of this work is illustrated 
in Fig. 1. As far as we are aware, the use of LMW hydrogels to encapsulate 
nioplexes derived from cationic niosomes for the controlled delivery of 
therapeutic molecules has not yet been reported.  
 
  
 
Fig. 1 Strategy used for the preparation of Fmoc–Phe–OH supramolecular hydrogels 
containing cationic nioplexes and FITC–ODN as a model nucleic acid. (A) Preparation 
of cationic niosomes containing FITC–ODN. (B) Illustration of the encapsulation and in 
vitro release studies of niosomal FITC–ODN from Fmoc–Phe–OH–based hydrogels 
(hydrogel-1) and Fmoc–Phe–OH hydrogels physically crosslinked with k-carrageenan 
(hydrogels-(2–4)). 
 
2. Results and discussion 
 
2.1 Synthesis and characterization of hydrogels containing nioplexes 
The synthesis of the amphiphilic lipid-1 (ESI, Fig. S1†) and the subsequent 
preparation of the cationic niosomal formulation were successfully 
accomplished following the experimental procedures described in our previous 
studies.30,31 Briefly, the cationic nioplexes used in this studied were made upon 
mixing lipid-1 with a non-ionic surfactant agent (polysorbate-80) and a 
fluorescently labelled oligodeoxynucleotide (FITC–ODN) as model antisense 
inhibitor (Fig. 1). The so obtained nioplexes were subsequently mixed with a 
suitable amount of the LMW gelator (Fmoc–Phe–OH) in phosphate buffered 
saline (PBS, pH 7.4) solution and gently heated in a sealed tube.26 After cooling 
the mixture down to room temperature, a transparent hydrogel was obtained 
(hydrogel-1; ESI, Fig. S2A†). Additionally, we prepared similar cationic 
nioplexes loaded-hydrogels but physically crosslinked with k-carrageenan with 
the aim of tuning the diffusional properties of the matrix under physiological 
conditions. Thus, nioplexes-containing Fmoc–Phe–OH–based hydrogels-(2–4) 
crosslinked with increasing concentration of k-carrageenan were prepared in 
PBS buffer (i.e., hydrogel-2, hydrogel-3 and hydrogel-4 containing 0.5, 0.8 and 
1% w/v of k-carrageenan, respectively) (ESI, Fig. S2B†). All hydrogels (1–4) 
were able to encapsulate nioplexes with high efficiency (EE > 90%) and the 
gelation ability of Fmoc–Phe–OH was not significantly influenced by the 
presence of both k-carrageenan and niosomes (ESI, Table S1†). 
The mechanical properties of representative composite hydrogels (i.e., 
hydrogel-1 and hydrogel-4) were investigated by oscillatory rheological 
measurements and compared to control gels prepared in the absence of 
niosomes (i.e., native hydrogel-5 and hydrogel-6, which was only tuned with k-
carrageenan at 1% w/v) (Fig. 2). The storage modulus (G’) and the loss 
modulus (G’’) were measured as a function of frequency (DFS, dynamic 
frequency sweep), strain (DSS, dynamic strain sweep) and time (DTS, dynamic 
time sweep). The viscoelastic nature of all samples was evidenced by G’ values 
ca. one order of magnitude greater than G’’ and a low dependence of G’ with 
the applied frequency. The addition of cationic niosomes to non-crosslinked 
hydrogels (i.e., hydrogel-1 vs. hydrogel-5) did not change the mechanical 
properties of the network, which displayed similar dissipation factor values (tan 
δ = G’’/G’ ≈ 0.15) (Fig. 2A; ESI, Table S1†), indicating a good response of both 
hydrogels to external forces. Interestingly, the incorporation of small amounts of 
k-carrageenan (hydrogel-6) produced an increase in G’ values compared to 
those obtained for the analogues non-crosslinked hydrogels (i.e., hydrogel-6 vs. 
hydrogel-5; hydrogel-4 vs. hydrogel-1) (Fig. 2A).45 Thus, the presence of k-
carrageenan seems to produce highly associated materials due to colloidal 
forces between the cationic niosomes and the anionic biopolymer. This was 
also reflected in the oligonucleotide release rates (vide infra). Again, the 
incorporation of cationic niosomes into hydrogels containing k-carrageenan 
(hydrogel-4) did not induce any significant change in the rheological properties 
when compared to hydrogel-6. 
On the other hand, DSS (dynamic strain sweep) measurements 
confirmed that all hydrogels remained intact while applied an oscillation stress 
within the linear viscoelastic regime (Fig. 2B; ESI, Fig. S3†). The presence of k-
carrageenan in the formulations produced only slight differences in the critical 
strain (ESI, Table S1†). Above the critical strain, crosslinked hydrogels induced 
a slighter resistance to the shear stress (γ) until G’’ exceeded G’ (i.e., γ at break 
= 68% vs. 43% for hydrogel-6 and hydrogel-5, respectively). The encapsulation 
of cationic niosomes into the gel matrices also increased slightly the critical 
strain γc values in comparison to native hydrogels (i.e., γc 16.6% and 20% for 
hydrogel-1 and hydrogel-4 vs. 13% and 13.4% for hydrogel-5 and hydrogel-6, 
respectively) (ESI, Fig. S3 and Table S1†). A similar behaviour was observed in 
the resistance the hybrid gels to shear stress (e.g., γ at break = 87% vs. 68% for 
hydrogel-4 and hydrogel-6, respectively). These differences were also observed 
for hydrogel-1 when compared to the corresponding native material. These 
results suggest that the presence of k-carrageenan and cationic niosomes 
within the supramolecular gel network could induce certain deformations in the 
systems under specific stress conditions, thus increasing the hydrogel rigidity 
and the corresponding shear stress resistance.46 Finally, DTS (dynamic time 
sweep) measurements confirmed the temporal stability of the supramolecular 
hydrogels within the viscoelastic regime (0.1% strain, 1 Hz frequency) (ESI, Fig. 
S4†). 
 
 
 
Fig. 2. Comparative rheological DFS (A) and DSS (B) measurements between 
hydrogel-1 and native hydrogel (hydrogel-5) (left); native hydrogel (hydrogel-5; without 
cationic vesicles) and physically crosslinked hydrogel with k carrageenan (hydrogel-6; 
without cationic vesicles) (middle); hydrogel-4 and hydrogel-6 (right). The arrows in 
DSS plots indicate the cross-point between G’ and G’’ (γ at break). The hydrogels were 
prepared in PBS (pH 7.4) and measured at room temperature (25 ºC). 
 
2.2 Small-angle X-ray scattering measurements 
The behavior of lipid-1 was investigated in aqueous media and their 
diffraction patterns (SAXS and WAXS experiments) were recorded at several 
temperatures (Fig. 3). SAXS curves were identical at both 25 ºC and 37 ºC 
whereas some increased background was appreciated around q = 2 nm-1 at 45 
ºC (Fig. 3A). A partial fusion was observed at 55 ºC with the presence of a band 
centered at q = 1.94 nm-1 although the peaks did not show appreciable 
changes. At 55 ºC, a complete fusion was observed and the band only 
remained in the SAXS domain. 
 
 
 
Fig. 3 (A) Scattered intensity of the fully hydrated lipid as a function of dispersion vector 
q at different temperatures. (B) WAXS spectra at several temperatures of the fully 
hydrated lipid as a function of scattering vector modulus q. 
 
Importantly, the SAXS pattern at 50 ºC did not change as a function of 
time (the three consecutive acquisitions were identical within experimental 
error), suggesting the coexistence of the lamellar and melted phases at this 
temperature. Therefore, we carried out the ODN encapsulation and release 
studies below this temperature in order to ensure the integrity of the vesicles 
during the experiments. 
Using the same range of differing temperatures, the WAXS region (Fig. 
3B) showed a single peak for the samples, which determined a lamellar order. 
This experiment confirmed a slight shift to smaller q values due to the increased 
mobility of the hydrophobic chains. This rise showed an interchain distance 
increase from 0.417 nm to 0.425 nm, which in turn implied a density decrease 
of about 3.5%. 
Additionally, the fitting of the experimental scattering data recorded at 25 
ºC was consistent with a lamellar model (Fig. 4A). It is noteworthy the absence 
of the expected second peak for the lamellar arrangement. This is related to the 
electronic profile of the lamellae coupled with the interlamellar distance. This 
can be appreciated from the single lamellae curve shown in red. The first 
minimum coincides with the position where the second peak should appear. Fig. 
4B shows the corresponding electronic density profile for the lamellae 
compared with the electronic density profile obtained from the Fourier 
reconstruction using the three visible peaks. Although both electronic profiles 
are consistent, we believe that our model profile is more realistic in the sense 
that there is not a physical reason for the secondary minima around ±1 nm from 
the bilayer center. From the electronic profile and the known volume and 
electron composition of the molecule we determined a hydrophobic bilayer half 
thickness of 1.43 ± 0.1 nm, a total bilayer thickness of 4.8 ± 0.1 nm, an area per 
molecule of 0.541 ± 0.003 nm2 and 13 ± 2 water molecules per polar head. This 
amount of water roughly corresponds to a 30% hydration. Furthermore, the 
sharpness of the peaks suggests a strong correlation between the bilayers, 
which corresponds to 28 ± 2 correlated bilayers, according to the model. 
 
 
Fig. 4 (A) SAXS intensity as a function of dispersion vector q of the fully hydrated lipid 
at 25 ºC (open black squares), fitted profile (black line) and bilayer form factor (red 
line). (B) Electronic density profile corresponding to the fitting in Fig. 3. Black line 
corresponds to the MCG profile and the red line to the Fourier reconstruction. The 
Fourier reconstruction was scaled to produce the same integral as the MCG model. 
 
2.3 In vitro release studies 
As mentioned above, in order to investigate and validate the efficacy of 
hydrogels-(1–4) as drug carriers, we studied the release kinetics of 
physiologically important biomolecules like oligonucleotides, which are involved 
in well-known gene regulation processes.47,48 The interaction between 
fluorescently labelled oligodeoxynucleotide FITC–ODN49 and cationic niosomes 
afforded the corresponding complexes (nioplexes) (Fig. 1A) with an optimal 
amine to phosphate (N/P) charge ratio of 14 as determined by the 
electrophoretic mobility shift assay (EMSA) (Fig. 5). 
In vitro release studies of the composite hydrogels made of Fmoc–Phe–
OH and (FITC–ODN)-loaded cationic nioplexes (1–4) were performed at 37 ºC 
to emulate physiological conditions. As a reservoir for the release, hydrogels-
(1–4) were immersed in PBS solution and aliquots were removed at regular 
intervals and analyzed by fluorescence spectroscopy according to a proper 
standard curve of FITC–ODN in solution (r2 > 0.99) (ESI, Fig. S5†). The 
removed volume was always replaced by the same amount of fresh buffer. In 
the case of hydrogel-1, the release kinetics was controlled by erosion of the 
polymeric matrix and ca. 90% of the FITC–ODN was rapidly liberated in ca. 1.5 
h (Fig. 6). 
 
  
Fig. 5. Electrophoretic mobility shift assay (EMSA). FITC–ODN was complexed 
with growing cationic niosomes N/P charge ratios in 100 mM of PBS in a native 
polyacrylamide gel (20%) at 150 V and 25 ºC. Bands were stained with SYBR-
Green II and bromophenol blue was used as a marker (mk). The disappearance 
of the FITC–ODN band indicated the completion of the complex formation (i.e., 
N/P ratio = 12). 
 
It is well-accepted that the rate of drug release can be modulated by 
adding additional ligands to the gel networks like synthetic molecules50 and 
biopolymers51,52 as crosslinking agents. This convenient strategy has helped to 
improve composite formulations and prolong the release of both small 
therapeutic drugs and macromolecules.53 This encouraged us to incorporate in 
our hydrogel formulation growing concentrations of k-carrageenan (i.e., 0.5, 0.8 
and 1%; hydrogel-2, hydrogel-3 and hydrogel-4, respectively)54 that would act 
as a physical crosslinking agent. The total cumulative release profiles of 
niosomal FITC–ODN complexes from these hydrogels crosslinked with k 
carrageenan are shown in Fig. 7. In general, the incorporation of the biopolymer 
within the supramolecular gel network made of Fmoc–Phe–OH prolonged 
considerably the FITC–ODN releasing time compared to that observed for 
hydrogel-1. Specifically, ca. 80–90% of FITC–ODN was available in the 
receptor phase after 5 h of incubation of hydrogels-(2–4). This result suggests a 
fall in hydrogel erosion processes induced by the presence of the biopolymer.55 
Furthermore, it is worth mentioning that the presence of k-carrageenan in the 
formulation was able to reduce the initial burst release during the first few 
minutes of the experiment (19% vs. 8% for hydrogel-1 and hydrogels-(2–4), 
respectively) (Fig. 6A and 7). This was probably due to the increase of the 
entanglement density of the non-covalently crosslinked hydrogels. 
Although the obtained niosomal FITC–ODN release profiles from 
physically crosslinked hydrogels-(2–4) were similar, the faster release was 
observed for hydrogel-4 having the highest concentration of k-carrageenan (1% 
w/v). This could be explained by the increase of the hydrophilic character of the 
hydrogel-4 network in which additional biopolymer may contribute to a better 
dissolution of the swollen supramolecular matrix and thus promoting hydrogel 
erosion processes and thereby accelerating the drug release. 
The analysis of the niosomal release was also studied by native 
polyacrylamide gel electrophoresis (PAGE) in order to clarify whether the 
presence of the cationic niosomes loaded in the supramolecular hydrogel could 
delay and control the oligonucleotide release from the supramolecular hydrogel. 
 
  
Fig. 6 (A) Cumulative release profile of the niosomal formulation containing FITC–ODN 
from hydrogel-1 in PBS solution at 37 ºC, along with the fitted curve (n = 2) according 
to Korsmeyer–Peppas equation [eqn (4)]. (B) log–log plot showing the monomial 
relationship between FITC–ODN concentration and time. Model fitting parameters are 
given in the ESI (Table S3†). 
 
The in vitro control release was carried out as described above and the 
collected aliquots in PBS were analyzed by PAGE (Fig. S7†). As a control, the 
same release experiment was also studied in the presence of 100 mM Triton-
X100 (Fig. S7B†). As displayed in Fig. S7A,† the oligonucleotide is partially 
released from the hydrogel at different times which suggests the presence of 
cationic niosomes might control the FITC–ODN liberation through the hydrogel. 
To corroborate these findings, Triton-X100 solution was added at the beginning 
of the experiment in order to solubilize the niosomal component and thus 
generate the unformulated FITC–ODN release in the receptor phase.56 As 
expected, native PAGE gels confirmed the use of the surfactant generated a 
faster oligonucleotide release at the first times of the release experiment (at t = 
15 min et seq). This effect was also confirmed from the analyses of the 
anticipated band intensities. However, it was very difficult to visualize and 
confirm the presence of intact niosomal particles in the receptor phase by 
monitoring the release by native PAGE. 
 
  
Fig. 7 Cumulative release profiles and corresponding fitted curves (n = 2; according to 
Korsmeyer–Peppas equation [eqn (4)]) of the niosomal formulation containing FITC–
ODN from (A) hydrogel-2, (B) hydrogel-3 and (C) hydrogel-4 in PBS solutions at 37 ºC. 
Hydrogels were crosslinked with growing concentrations of k-carrageenan (0.5, 0.8 and 
1% w/v, respectively). Model fitting parameters and log–log plots are given in the ESI 
(Table S3 and Fig. S8†). The combination of the three release curves is displayed in 
the ESI (Fig. S6†). 
 
2.4 Drug release mathematical models 
The release data obtained for hydrogels-(1–4) was fitted according to 
three theoretical models that describe the diffusion related drug release from 
polymeric matrices. The selected models are defined by the Higuchi equation 
[eqn (3)], Korsmeyer–Peppas equation for burst release [eqn (4)] and Weibull 
equations for delayed release [eqn (5)].57–59 The first two models are short time 
approximations and generally limited to the first 60% of the release.60 The total 
FITC–ODN cumulative release from all hydrogel matrices was found to follow a 
Korsmeyer–Peppas kinetic model (i.e., their regression coefficients were 
greater (r2 > 0.99) than the rest of theoretical models (ESI, Tables S2–S4†)). 
According to Peppas' equation, the FITC–ODN release afforded n (diffusion 
coefficient) values ranging from 0.51 to 0.56. These exponent values are in 
close agreement with those predicted for non-Fickian diffusions.57 This 
anomalous transport suggests the presence of specific interactions and/or 
erosion mechanisms between cationic niosomes and the fibrous gel matrices. 
Overall, the results of this study suggest a diffusion controlled release as the 
main process that govern the liberation of FITC–ODN from the hydrogel 
matrices.61 
 
2.5 MTT assay 
To evaluate the cytocompatibility of Fmoc–Phe hydrogels crosslinked 
with k-carrageenan in combination with cationic niosomes and nioplexes, a MTT 
reductase assay was carried out.62 This assay is based on the tetrazolium salt 
reduction to formazan crystals by a dehydrogenase that is present in 
mitochondria. Then, untreated cells (Blank) and HeLa cells only treated with 
hydrogel-3 (Mock) were selected as our negative controls. Furthermore, cationic 
niosomes-loaded hydrogel-3 without forming complexes at two concentrations 
(1.7 µM and 4.2 µM, referred to lipid concentration) besides hydrogel-3 
containing cationic nioplexes (120 nM and 300 nM, referred to oligonucleotide 
concentration) were also evaluated. 
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Fig. 8 (A) Cell viability studies according to the MTT assay in HeLa cells in the 
presence of hydrogel-3 (Mock) and hydrogel-3 containing both cationic niosomes (at 
1.7 µM and 4.2 µM) and cationic nioplexes (at 120 nM and 300 nM). Nioplexes were 
obtained from a N/P ratio of 14 according to EMSA assays. Blank corresponds to 
untreated HeLa cells. Data were means ± SD of six independent experiments and the 
normalized cellular viability was expressed as a percentage to the untreated control 
cells. A phosphorothioate oligonucleotide complementary to the mRNA luciferase gene 
(5’-CGT TTC CTT TGT TCT GGA-3’) was used as an antisense oligonucleotide model. 
(B) HeLa cell morphology images of untreated cells (blank). (C) HeLa cell morphology 
images in the presence of cationic niosomes. (D) HeLa cell morphology images in the 
presence of cationic nioplexes. HeLa cell images in the presence of mock (only 
hydrogel) are displayed in Fig. S9.† 
 
When cultured for 24 h, hydrogel-3 was totally degraded whereas both 
cationic niosomes and nioplexes were released from the hydrogel. As displayed 
in Fig. 8A, the anticipated hydrogel and cationic niosome hybrids did not show 
any evidence of toxicity obtaining good cellular viabilities (up to ca. 80%). These 
results also demonstrated normal cell morphology as illustrated in Fig. 8B–D 
which confirmed the suitability of the hydrogel-3 to be used in cell culture. 
 
2.6 Preliminary in vitro drug delivery studies 
Firstly, we selected a phosphorothioate oligonucleotide complementary 
to the mRNA luciferase gene63 to evaluate the gene silencing properties and 
therefore confirm the niosomal release from hydrogels but unfortunately the 
presence of Fmoc–Phe inhibited the luciferase gene, as described for other Phe 
analogues.64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Flow cytometry analysis of GFP expression in HeLa cells. (A) Normal cell 
population (negative control). (B) Control. (C) Flow cytometry analysis for GFP 
released from hydrogel-3. (D) Flow cytometry analysis for niosomal GFP complexes 
(N/P ratio of 4). (E) Flow cytometry analysis for niosomal GFP complexes (N/P ratio of 
6). A flow cytometry histogram shows a slight shift between cell population containing 
GFP and untreated cells after 24 h incubation 
 
For this reason, we moved forward and selected pMax-GFP plasmid as a 
model to carry out transfection studies. For the preparation of the niosomal 
formulation, we used the same protocol as described by our research group 
previously.30 After forming GFP nioplexes at two N/P ratio (4 and 6), particles 
were entrapped in hydrogel-3 and placed in a transwell insert system. As a 
control experiment, GFP plasmid, in the absence of cationic niosomes, was 
encapsulated within the hydrogel. After 24 h of incubation, hydrogel was 
practically degraded and cellular uptake was analyzed by flow cytometry (Fig. 
9). Firstly, we selected a normal gate (R1) for HeLa cells based on their light 
scatter properties, which distinguished single cells by relative size (Fig. 9A). 
This allowed us to analyze specific populations and selectively focus on the 
relationship between fluorescently labeled and unlabeled cell populations. 
As displayed in Fig. 9E, our results suggest that GFP was taken more 
efficiently by HeLa cells when GFP-forming complexes with the lipid-1 at N/P 
ratio of 6 were entrapped in hydrogel-3 (17%) according to the gate positive 
population (Fig. 9E). When we compare this result with the transfection 
promoted by the unformulated GFP (Fig. 9C), the cell population was 
transfected roughly 4.6 per cent. Similar results were obtained in the case of 
GFP-forming complexes at N/P ratio of 4 (3.6%) (Fig. 9D). This difference can 
be also observed in the flow cytometry histogram, which shows a slight 
difference shift between fluorescent labelled and unlabelled cell populations. 
This result suggests that part of the nioplexes integrity were unaltered 
when released from the hydrogel and continued to be active during the 
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transfection process took place. These preliminary observations look promising 
and further studies involving hydrogelator concentration, optimized formulations 
and use of alternative crosslinking agents are currently investigated. 
3. Experimental Section 
3.1. Materials. 
All reagents employed in this work were used as received without further purification. 
Polysorbate-80 (Tween-80), Fmoc-L-phenylalanine (Fmoc-Phe-OH), ĸ-carrageenan and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent) were 
purchased from Sigma-Aldrich. A fluorescently labelled oligodeoxynucleotide sequence 
(5’-FITC-CGG AGG TAC ATT CGA CTT GA-3’; FITC-ODN) was synthesized in house in a 
DNA/RNA synthesizer ABI 3400 and purified by semi-preparative HPLC according to 
DMTon-based protocols. FITC (fluorescein isothiocyanate) was automatically coupled 
at the 5’-termini via phosphoramidite chemistry. Standard phosphoramidites and 
ancillary reagents used for the synthesis of FITC-ODN were purchased from Link 
Technologies. Phosphorothioate oligonucleotide of sequence 5’-CGT TTC CTT TGT TCT 
GGA-3’ was purchased from Proligo (Sigma-Aldrich). The amino lipid 1 was synthesized 
according to the literature.30 UV-Vis and fluorescence measurements were recorded 
on a Varian Cary BIO 50 UV/VIS/NIR Spectrometer and a Fluoromax-4 
spectrofluorometer, respectively. Flow cytometer analyses were carried out in a 
Guava® easyCyte 8HT instrument (Millipore). 
 
3.2 Methods. 
3.2.1 Electrophoretic mobility shift assay (EMSA). FITC-ODN (0.5 µM) was 
properly mixed with growing concentrations of nioplexes dispersed in PBS (working 
concentration = 500 µM), which gave rise to nioplexes/FITC-ODN molar ratios ranging 
from 0.5 to 16. The resultant complexes were analyzed by using electrophoresis on a 
20% polyacrylamide gel at 150 V for 6 h at 25 ºC in 1X TBE buffer. The polyacrylamide 
gel electrophoresis (PAGE) was immersed in 1X TBE buffer (200 µL) and stained with 
SYBR-Green (20 µL) (shaking 15 min at room temperature). Pictures were taken with a 
Fujifilm LAS-1000 Intelligent Dark Box II and IR-LAS-1000 Lite v1.2 instruments. 
3.2.2 Rheology. Oscillatory rheological measurements were carried out in an 
AR 2000 Advanced rheometer (TA Instruments) equipped with a Julabo C cooling 
system. A plain-plate geometry (20 mm, stainless steel), a 1000 μm gap setting and a 
torque setting of 40,000 dynes cm-2 at 25 °C were used for the measurements. After 
obtaining the supramolecular hydrogels in the absence and in the presence of 
nioplexes (total gel volume = 2 mL), three different experiments were carried: (1) 
Dynamic Frequency Sweep (DFS): variation of G' and G'' with frequency (from 0.1 to 10 
Hz at 0.1% strain); (2) Dynamic Strain Sweep (DSS): variation of G' and G'' with strain 
(from 0.01 to 100%) and (3) Dynamic Time Sweep (DTS): variation of G' and G'' with 
time maintaining both the strain and frequency values constant within the linear 
viscoelastic regime (strain = 0.1% strain; frequency = 1 Hz).  
3.3 General procedures. 
3.3.1 General procedure for the synthesis of cationic nioplexes-FITC-ODN 
complexes (lipoplexes). Cationic nioplexes were made of Lipid-1 and non-ionic 
surfactant agent (Polysorbate-80) in PBS (working concentration = 500 µM) at an 
optimal N/P ratio of 14 were mixed with a fixed amount of FITC-ODN. The mixture was 
vortexed and sonicated for 20 sec. The resultant complexes were obtained by 
incubating the samples at 37 ºC for 30 min. 
3.3.2 General Procedure for supramolecular gel formation-loaded cationic 
nioplexes. Hydrogel-1 was obtained as follows: Fmoc-Phe-OH (10 mg; 0.026 mmol) 
was placed into a screw-capped glass vial (4 cm length × 1 cm diameter) and gently 
dissolved in PBS (3.5 mL, pH 7.4) at 70 ºC. After the solution reached 40 ºC, the 
hydrogelator (500 µL) together with cationic nioplexes:FITC-ODN nioplexes (0.08-0.1 
µM) were carefully mixed for 5 min. The mixture was cooled down to room 
temperature affording the corresponding nioplexe-containing supramolecular 
hydrogel.  
Hydrogels-(2-4) were obtained as follows: Fmoc-Phe-OH (10 mg; 0.026 mmol) 
and the corresponding amount of ĸ-carregeenan (0.5, 0.8 or 1% w/v, respectively) 
were placed into a screw-capped glass vial (4 cm length × 1 cm diameter) and gently 
dissolved in 100 mM PBS (3 mL, pH 7.4) at 70 ºC. When the three solutions reached 45 
ºC, the mixture of hydrogelator and ĸ-carregeenan (500 µL) together with cationic 
nioplexes:FITC-ODN nioplexes (0.08-0.1 µM) were carefully mixed for 5 min. Finally, 
the three solutions were cooled down to room temperature affording the 
supramolecular hybrid hydrogels containing (FITC-ODN)-loaded cationic nioplexes 
(hydrogel-2, hydrogel-3 and hydrogel-4 for 0.5, 0.8 or 1% w/v, respectively).   
Hydrogel-7 was simply obtained by mixing the required amount of FITC-ODN in 
500 µL of the hydrogelator solution. The supramolecular hydrogel containing FITC-ODN 
was obtained after cooling the solution to room temperature.  
The encapsulation efficiency (EE) of the supramolecular hybrid materials was 
calculated analyzing the initial FITC-ODN amount (starting material) and the remaining 
mass of FITC-ODN in the receptor phase (at t = 0) [eq. 1]. 
 
 
3.3.3 Small-angle X-ray scattering (SAXS). Sample preparation for SAXS 
measurements: Lipid-1 in its powder form was introduced into a glass capillary. A few 
microliters of PBS buffer was added on top and the ensemble was centrifuged to get 
the powder in contact with the buffer. Measurements were performed after 48 h 
incubation at room temperature. The reproducibility of the measurement was 
assessed by measuring again the sample after one week. SAXS and WAXS Analysis: 
SAXS and WAXS patterns were obtained at the same time using a S3-MICRO (Hecus X-
ray systems, Graz, Austria) coupled to a GENIX-Fox 3D X-ray source (Xenocs, Grenoble, 
France) working at 50 Kv and 1 mA. This provides a detector focused X-ray beam with λ 
= 1.542 Å at Cu Kα line with more than 97% purity and less than 0.3% Kβ. The two 
detectors are PSD 50 (Hecus, Graz, Austria). The working q-range were 0.1 ≤ q ≤ 6 
nm−1, in the small angle range and 13 ≤ q ≤ 19 nm−1 in the wide angle range, where q = 
4 π / λ sin(θ/2) is the modulus of the scattering wave vector, θ the scattering angle and 
λ the wavelength. SAXS patterns were analyzed in terms of a global model using the 
MCG model of Pabst and coworkers.65 The analysis technique models the full q-range 
in the SAXS regime, including Bragg peaks and diffuse scattering. The bilayer electronic 
density profile was calculated as the sum of three Gaussian, one corresponding to the 
methyl contributions and the two others corresponding to the polar heads, as a 
difference with respect to the model of Pabst and co-workers.65,66 We also 
incorporated a constant term through the hydrophobic part of the bilayer to give 
account of the methylene contribution.67 The interbilayer ordering was taken into 
account considering the modified Caillé model as in the work of Pabst co-workers.  
The volume of the lipid has been estimated to be 0.911 nm3 by using 0.812 nm3 
for the hydrocarbon chains and 0.099 nm3 both obtained from partial group volumes: 
+ 0.009 per -O- (calculated from the density of 1,1-diethoxy butane); 0.0027 per NH2 
and 0 for trisubstituted C).68 To properly scale the electronic density, we have 
considered the volume as well as the total number of electrons. From this calculation 
also the number of water molecules per polar head was obtained. 
The Fourier reconstruction was performed using the same procedure as J. 
Pereira-Lachataignerais and co-workers69 and using (- nil + -) for the phasing of the first 
4 reflections. This phasing gives a sensible result and coincides with the results 
obtained by Pereira-Lachataignerais and co-workers. 
3.3.4 In vitro control release experiments. Release experiments were carried 
out by adding 1 mL of phosphate buffered saline (PBS) solution (pH 7.4) in 500 µL of 
supramolecular hydrogels (1-4 and 7). Hydrogels were placed into a screw-capped 
glass vial (4 cm length × 1 cm diameter) and were incubated at 37 ºC. At specific time 
intervals, aliquots (1 mL) were carefully removed for subsequent fluorescence analysis. 
The removed volume was replaced with fresh PBS buffer (1 mL). The fluorescence of 
each aliquot (1 mL) was measured by using excitation and emission wavelengths of 466 
and 513 nm, respectively. The cumulative FITC-ODN release was obtained by 
calculating the total mass detected in the aliquots [eq. 2]. The FITC-ODN concentration 
was determined via interpolation from a separately constructed standard curve of 
fluorescence vs. concentration (ESI, Figure S5).  
In vitro control release was also studied by native polyacrylamide 
electrophoresis (PAGE) gel (20%) (for further details, see Supplementary Information). 
Cationic nioplexes (1 µM FITC-ODN) were embedded and aliquots (50 µL) were taken 
at different times. Aliquots were loaded in the presence of 50% glycerol (2 µL) in 1X 
TBE and gels were run at 150 V and at 25 ºC for six hours. PAGE gel was stained with 
SYBR-Green (20 µL) and gel was stirred for 15 minutes. Images were analyzed using 
ImageJ software (US National Institute of Health).  
 
 
3.4 Mathematical models. 
Release curves were fitted according to Higuchi [eq. 3], Korsmeyer-Peppas [eq. 4] and 
Weibull [eq. 5] empirical equations. In Higuchi model, the fraction of drug released is 
proportional to the square root of time; where Mt and M∞ are the cumulative and the 
maximal amounts of drug released at time t, respectively. K is a constant related to the 
formulation. In the case of Korsmeyer-Peppas equation, k is a rate constant and n is 
the release exponent that characterizes the release mechanism (e.g. n = 0.5 for Fickian 
diffusions and [1/2 < n < 1)) for non-Fickian diffusions. For the Weibull model, b 
parameter describes the diffusional mechanism of the drug release. When b ≤ 0.75 the 
Fickian diffusion is the main mechanism while for b values 0.75 < b <1 diffusion 
mechanism together with a contribution of another complex release processes can 
govern the liberation of the molecule.  
 
 
 
3.5 MTT assay. 
HeLa cells (6000 cells/well) were cultured in a Transwell HTS 96-well plate at 37 ºC 
with a humidified incubator, 5% CO2 overnight to achieve 60% confluence in DMEM 
supplemented with 10% FBS. Cells only treated with DMEM served as a negative 
control group (Blank). Hydrogel-3 was previously heated up at 80 ºC and filtered 
through 0.2 µm membrane. (15 µL of Hydrogel-3; Mock), Hydrogel-3 containing only 
cationic niosomes at two cationic lipid concentrations (1.7 µM and 4.2 µM) and 
cationic nioplexes-loaded Hydrogel-3 at two oligonucleotide concentration (120 nM 
and 300 nM) were placed on top of the transwell filters and were exposed to HeLa 
cells for 24 h (total volume = 200 µL). After removing the supernatant and washed with 
PBS (200 µL), HeLa cells were incubated at 37 ºC with fresh medium (200 µL) for 
additional 2 h. Then, 25 µL of MTT solution (5 g L-1 in PBS) were added and HeLa cells 
were incubated for another 2 h at 37 ºC. The resultant formazan crystals were 
dissolved in DMSO (200 µL) and the absorbance was measured at 560 nm. All 
experiments were carried out in sextuplicate. 
 
3.6 In vitro drug delivery studies and flow cytometry analysis. 
HeLa cells (105 cells/well) were seeded in a 24 well-plate in a humidified incubator, 5% 
CO2 in DMEM supplemented with 10% FBS (1 mL) to achieve a 60 % confluence. 
Twenty-four hours after seeding, fresh medium without antibiotic (600 µL) was 
replaced. Hydrogelator and ĸ-carrageenan at specific concentrations were dissolved in 
PBS as described previously and filtered through 0.2 µm membrane. GFP plasmid 
(negative control) and cationic nioplexes (at N/P ratio of 4 and 6) containing GFP were 
entrapped within the preformed hydrogel (50 µL) the day before. A transwell insert 
system was introduced and the three hydrogels were placed in. After 24 hours of 
incubation, DMEM was discharged and cells were washed twice with PBS (500 µL). 
Cells were collected by trypsinization, centrifugated and resuspended in PBS (300 µL). 
Finally, transfection efficiencies of the three supramolecular hydrogels was analyzed by 
flow cytometry.  
Conclusions 
In conclusion, this work demonstrates the possibility of using supramolecular 
hydrogels as versatile carriers for oligonucleotideloaded nioplexes. As a proof-of-
concept, a fluorescently labelled oligodeoxynucleotide (FITC–ODN) was incorporated 
into cationic niosomes based on an amphiphilic lipid (i.e., lipid-1) and subsequently 
embedded into biocompatible 3D supramolecular hydrogels based on Fmoc–Phe–OH 
(pH 7.4). In some cases, small amounts of k-carrageenan were also added into the gel 
formulations in order to investigate the crosslinking effect on the drug diffusion 
through the matrix. Small-angle X-ray scattering (SAXS) measurements showed the 
formation of lamellar structures for the glycerol-based lipid-1, which remained 
practically constant in a temperature range between 25 ºC and 45 ºC. Furthermore, 
the strong correlation and low flexibility of the bilayers deduced from the SAXS curves 
supported the stability of the nioplexes under the conditions used in this work. It is 
worth mentioning that a complete fusion of the lipid-1 was observed in the SAXS 
pattern when the temperature was increased at 55 ºC. Interestingly, this property was 
previously not detected for the serinol-based lipid analogue.57  
The results of this investigation showed that Fmoc–Phe–OH- based supramolecular 
hydrogels (without k-carrageenan additive) liberated almost the total amount of FITC–
ODN in ca. 1.5 h. Nevertheless, physically crosslinked hydrogels with k-carrageenan 
were able to prolong the release time of the niosomal oligonucleotide up to 5 h. This 
increase was presumably due to a reduction of both erosion processes and burst 
release effects by the presence of the hydrophilic biopolymer. In all cases, the 
niosomal oligonucleotide release was well fitted by using the Korsmeyer–Peppas 
kinetics model. The liberation of FITC–ODN was governed by non-Fickian diffusion, 
which suggested specific interactions between the cationic nioplexes and the gel 
networks. Moreover, these hybrid materials were found to be non-toxic in cell culture 
(i.e., HeLa cells). To demonstrate whether nioplexes were still active when released 
from hydrogels, niosomal formulations containing GFP plasmid at their optimal N/P 
ratio were loaded within hydrogels and transfection efficiencies were evaluated by 
flow cytometry. These preliminary results showed better efficiencies for 
niosomalloaded hydrogels than unformulated GFP-hydrogel materials, which indicated 
the presence of intact particles upon the release. We are currently investigating 
alternative approaches to improve this transfection efficiency by adding new 
crosslinking agents and the use of other peptide-based supramolecular gelators in 
order to obtain more robust and efficient vehicles for biomolecules 
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 Figure S1. 1H-NMR of lipid-1. Reaction was performed under argon atmosphere. 1H-NMR 
spectra was recorded in CDCl3 at 25 °C on a Varian Mercury 400 MHz spectrometer. The 
proton signal for residual non-deuterated solvent (δ 7.26) was used as an internal referente. 
Chemical shifts are reported in parts per million (ppm), coupling constants (J) in Hz and 
multiplicity as follows: t (triplet), dd (doublet of doublets), m (multiplet): 1H-NMR (400 MHz, 
CDCl3) δ (ppm) 3.59 (m, 1H; CH-O), 3.46 (m, 2H; CH2-O), 3.40 (m, 4H; 2 CH2-O), 2.83 (dd, J = 
13.4 Hz, 3.9 Hz; 1H; CH-N), 2.71 (dd, J = 13.2 Hz, 4.0 Hz; 1H; CH-N), 1.53 (m, 4H; 2 CH2-C), 1.23 
(m, 40 H; alkyl chain), 0.86 (t, J = 7.0 Hz, 6H; 2 CH3-CH2). 
 
 
 
Figure S2. Supramolecular hydrogel picture selections. (A) N-Fmoc-protected amino 
acid (Fmoc-Phe-OH) containing cationic niosomes (hydrogel-1). (B) N-Fmoc-protected 
amino acid (Fmoc-Phe-OH) crosslinked with ĸ-carrageenan (1%, w/v) (hydrogel-4). 
Table S1 Encapsulation efficiencies (EE) of hydrogels-(1-4) and hydrogel-7. Native 
hydrogels (hydrogel-5 and hydrogel-6) were used as controls for comparison purposes.a 
Entry Sample 
κ-C 
(%, 
w/v) 
Cationic 
niosomes: 
FITC-
ODN 
EE  
(%) 
G' 
(kPa) 
G'' 
(kPa) 
γ 
(%) 
γc 
(%) 
tan 
δ 
1 Hydrogel-1 - yes 94.0±1.5 2.68 0.40 - 16.6 0.15 
2 Hydrogel-2 0.5 yes 97.0±0.5 nd nd nd nd nd 
3 Hydrogel-3 0.8 yes 98.0±0.4 nd nd nd nd nd 
4 Hydrogel-4 1 yes 98.0±0.8 5.29 0.57 87 20.0 0.10 
5 Hydrogel-5 - native - 2.38 0.33 43 13.0 0.14 
6 Hydrogel-6 1 native - 7.81 0.72 68 13.4 0.09 
7 Hydrogel-7 1 
only  
FITC-
ODN 
98.0±0.2 nd nd nd nd nd 
a
 Abbreviations and definitions: κ-C = κ-carrageenan; G' = storage modulus; G'' = loss modulus; γ = 
strain at break (yield stress); γc = critical strain; tan δ = loss factor (G''/G'); nd = not determined. Reported 
data are means of three independent experiments ± S.D. 
 
 
Figure S3. DSS measurements and critical strain (γc). 
A 
 
B 
 
Figure S4. DTS measurements of hydrogel-1, hydrogel-4, hydrogel-5 and hydrogel-6. 
(A) Left: Hydrogel containing cationic niosomes (hydrogel-1). Right: hydrogel 
crosslinked with ĸ-carrageenan (1%, w/v) and containing cationic niosomes (hydrogel-
4). (B) Left: Native hydrogel (without cationic niosomes and ĸ-carrageenan; hydrogel-
5). Right: Native hydrogel (without cationic niosomes but containing ĸ-carrageenan; 
hydrogel-6).  
 
 
 
Figure S5. Standard curve of FITC-ODN. 
 
Table S2. Model release parameters for hydrogels-(1-4) and hydrogel-7 according to 
Higuchi equation 
 
Entry Sample k r2 
1 Hydrogel-1 9.74 0.9891 
2 Hydrogel-2 6.90 0.9717 
3 Hydrogel-3 5.73 0.9765 
4 Hydrogel-4 5.12 0.9947 
5 Hydrogel-7 5.02 0.9971 
 
Table S3. Model release parameters for hydrogels-(1-4) and hydrogel-7 according to 
Korsmeyer-Peppas’ equation. The model was calculated for the first 60% of the FITC-
ODN release 
 
Entry Sample k n r2 
1 Hydrogel-1 7.63 0.56 0.9935 
2 Hydrogel-2 6.04 0.52 0.9940 
3 Hydrogel-3 5.38 0.51 0.9938 
4 Hydrogel-4 5.12 0.52 0.9952 
5 Hydrogel-7 2.83 0.62 0.9934 
 
Table S4. Model release parameters for hydrogels-(1-4) and hydrogel-7 according to 
Weibull equation 
 
Entry Sample a k b r2 
1 Hydrogel-1 137.8 0.013 0.77 0.9803 
2 Hydrogel-2 98.9 0.013 0.96 0.9647 
3 Hydrogel-3 94.5 0.011 0.93 0.9834 
4 Hydrogel-4 129.7 0.005 0.73 0.9949 
5 Hydrogel-7 152.4 0.003 0.76 0.9936 
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Figure S6. Combination of the three niosomal FITC-ODN cumulative release from 
hydrogels-(2-4).  
 
  
 
 
Figure S7. A. FITC-ODN release from hydrogel-3 containing cationic nioplexes 
analyzed by native gel polyacrylamide electrophoresis (PAGE). B. FITC-ODN release 
from hydrogel-3 containing cationic nioplexes analyzed by native gel polyacrylamide 
electrophoresis. 100 mM Triton X-100 was added to the PBS receptor phase at different 
times. The solubilization of the niosomes produced a liberation of the unformulated 
FITC-ODN. 
 
  
Figure S8. Release profiles of niosomal FITC-ODN from hydrogels-(1-4). 
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Figure S9. Cell morphology images of HeLa cells in the absence (left) and the presence 
of hydrogel-3 (mock) (right). 
 
 
 
